Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03835819
Title A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
University of Massachusetts Worcester Massachusetts 01605 United States Details
Northwell Cancer Institute Lake Success New York 11042 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field